Top

Reactions Weekly

Published in:

01-01-2023 | Hepatitis B | Case report

Doxorubicin/entecavir/immunosuppressants

Lack of efficacy, ALT elevation and hepatitis B reactivation: 4 case reports

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Amano H, et al. The use of electronic medical records-based big-data informatics to describe alt elevations higher than 1000 iu/l in patients with or without hepatitis b virus infection. Viruses 13: No. 11, Nov 2021. Available from: URL: http://doi.org/10.3390/v13112216

Title: Doxorubicin/entecavir/immunosuppressants
Lack of efficacy, ALT elevation and hepatitis B reactivation: 4 case reports
Publication date: 01-01-2023
Publisher: Springer International Publishing
Keywords: Hepatitis B
Rituximab
Entecavir
Rituximab
Prednisolone
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-30694-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Doxorubicin/entecavir/immunosuppressants

Lack of efficacy, ALT elevation and hepatitis B reactivation: 4 case reports

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Clozapine

Foscarnet/ganciclovir

Vincristine

Ad26.cov2-s/elasomeran/tozinameran

Methadone

Metronidazole/vancomycin